{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:06:55Z","timestamp":1791313615965,"version":"4.3.1"},"reference-count":186,"publisher":"Harborside Press, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>In recent years, immunotherapy has been increasingly incorporated into the clinical care of both pediatric and adult patients with B-cell acute lymphoblastic leukemia (B-ALL) to improve outcomes. Four main categories of immunotherapies are used in B-ALL: (1) unconjugated monoclonal antibodies (mAbs), (2) antibody\u2013drug conjugates (ADCs), (3) T-cell\u2013engaging antibodies, and (4) CAR T cells. Although mAbs such as rituximab are primarily used in adults, the other modalities have demonstrated efficacy in both pediatric and adult patients with B-ALL. Among ADCs, inotuzumab ozogamicin (InO) has proven effective as monotherapy for relapsed disease, leading to FDA approval for patients aged &gt;1 year with relapsed\/refractory B-ALL. InO is also being investigated in the upfront setting in combination with chemotherapy. Although results in adults have been promising, increased rates of infectious complications in chemotherapy courses post-InO have hampered progress of trials in children, adolescents, and young adults. T-cell\u2013engaging antibodies are now a standard component of therapy for most patients with newly diagnosed and relapsed B-ALL, following the successful integration of the bispecific T-cell\u2013engager blinatumomab into chemotherapy regimens for both adults and children. Recent studies support the possibility of using blinatumomab to replace some or even most of the intensive chemotherapy traditionally used in B-ALL treatment. CAR T-cell therapy has revolutionized the treatment of relapsed\/refractory B-ALL by targeting CD19, but challenges remain due to the loss of CAR T-cell persistence and antigen escape. Newer CAR T cells targeting CD22 or the combination of CD19 and CD22 are being studied to address the issue of antigen escape. Overall, immune-based therapies are now a mainstay of B-ALL therapy. This article reviews the efficacy and safety data of several immune-based therapies in B-ALL and discusses a number of outstanding questions and possible future directions for the use of immune-based approaches in the treatment of B-ALL.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7067","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:56:17Z","timestamp":1765979777000},"source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy in B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.6004","volume":"23","author":[{"given":"Kara L.","family":"Davis","sequence":"first","affiliation":[{"name":"Pediatric Hematology\/Oncology\/Stem Cell Transplant and Regenerative Medicine, Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Stanford University School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.O.","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology\/BMT, Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Rau","sequence":"additional","affiliation":[{"name":"Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children\u2019s Hospital, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"},{"name":"Department of Pediatrics, Seattle Children\u2019s Hospital, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"N Engl J Med","first-page":"1541","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger SP","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med 2015;373:1541\u20131552."},{"key":"B2","series-title":"J Clin Oncol","first-page":"2938","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui CH","year":"2015","unstructured":"Pui CH, Yang JJ, Hunger SP,  Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol 2015;33:2938\u20132948."},{"key":"B3","series-title":"Pediatr Blood Cancer","first-page":"e30585","article-title":"Children's Oncology Group blueprint for research: acute lymphoblastic leukemia","volume":"70","author":"Raetz EA","year":"2023","unstructured":"Raetz EA, Bhojwani D, Devidas M,  Children's Oncology Group blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer 2023;70(Suppl 6):e30585."},{"key":"B4","series-title":"N Engl J Med","first-page":"875","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta S","year":"2025","unstructured":"Gupta S, Rau RE, Kairalla JA,  Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N Engl J Med 2025;392:875\u2013891."},{"key":"B5","series-title":"N Engl J Med","first-page":"1572","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis IM","year":"2023","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS,  Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med 2023;388:1572\u20131581."},{"key":"B6","series-title":"JAMA","first-page":"833","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown PA","year":"2021","unstructured":"Brown PA, Ji L, Xu X,  Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA 2021;325:833\u2013842."},{"key":"B7","series-title":"JAMA","first-page":"843","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli F","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C,  Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA 2021;325:843\u2013854."},{"key":"B8","series-title":"J Clin Oncol","first-page":"956","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group protocol AALL1621","volume":"40","author":"O\u2019Brien MM","year":"2022","unstructured":"O\u2019Brien MM, Ji L, Shah NN,  Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group protocol AALL1621. J Clin Oncol 2022;40:956\u2013967."},{"key":"B9","series-title":"N Engl J Med","first-page":"1507","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude SL","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA,  Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507\u20131517."},{"key":"B10","series-title":"N Engl J Med","first-page":"439","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude SL","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J,  Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439\u2013448."},{"key":"B11","series-title":"N Engl J Med","first-page":"1044","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury S","year":"2016","unstructured":"Maury S, Chevret S, Thomas X,  Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med 2016;375:1044\u20131053."},{"key":"B12","series-title":"J Clin Oncol","first-page":"3880","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas DA","year":"2010","unstructured":"Thomas DA, O\u2019Brien S, Faderl S,  Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010;28:3880\u20133889."},{"key":"B13","series-title":"Blood","first-page":"4018","article-title":"A phase II study of pegylated asparaginase, cyclophosphamide, rituximab, and dasatinib added to the UCSF 8707 (Linker 4-drug) regimen with liposomal cytarabine CNS prophylaxis for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401","volume":"132","author":"Wieduwilt MJ","year":"2018","unstructured":"Wieduwilt MJ, Jonas BA, Schiller GJ,  A phase II study of pegylated asparaginase, cyclophosphamide, rituximab, and dasatinib added to the UCSF 8707 (Linker 4-drug) regimen with liposomal cytarabine CNS prophylaxis for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401. Blood 2018;132(Suppl 1):Abstract 4018."},{"key":"B14","series-title":"Blood","first-page":"1493","article-title":"Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL)","volume":"120","author":"Goekbuget N","year":"2012","unstructured":"Goekbuget N, Beck J, Brueggemann M,  Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL). Blood 2012;120(Suppl):Abstract 1493."},{"key":"B15","series-title":"Blood","first-page":"1903","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget N","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S,  Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood 2024;143:1903\u20131930."},{"key":"B16","series-title":"Leukemia","first-page":"1782","article-title":"Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia","volume":"37","author":"Hoshitsuki K","year":"2023","unstructured":"Hoshitsuki K, Zhou Y, Miller AM,  Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia. Leukemia 2023;37:1782\u20131791."},{"key":"B17","series-title":"Cancer","first-page":"3381","article-title":"Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis","volume":"127","author":"Sasaki K","year":"2021","unstructured":"Sasaki K, Kantarjian HM, Morita K,  Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis. Cancer 2021;127:3381\u20133389."},{"key":"B18","series-title":"J Immunol","first-page":"362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling JL","year":"2006","unstructured":"Teeling JL, Mackus WJ, Wiegman LJ,  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362\u2013371."},{"key":"B19","series-title":"Lancet Haematol","first-page":"e523","article-title":"Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial","volume":"7","author":"Jabbour E","year":"2020","unstructured":"Jabbour E, Richard-Carpentier G, Sasaki Y,  Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 2020;7:e523\u2013533."},{"key":"B20","series-title":"Br J Haematol","first-page":"763","article-title":"Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive\/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia","volume":"171","author":"Awasthi A","year":"2015","unstructured":"Awasthi A, Ayello J, Van de Ven C,  Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive\/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia. Br J Haematol 2015;171:763\u2013775."},{"key":"B21","series-title":"Pediatr Blood Cancer","first-page":"1171","article-title":"Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children's Oncology Group (COG) study ADVL04P2","volume":"62","author":"Raetz EA","year":"2015","unstructured":"Raetz EA, Cairo MS, Borowitz MJ,  Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatr Blood Cancer 2015;62:1171\u20131175."},{"key":"B22","series-title":"Blood Adv","first-page":"449","article-title":"Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"4","author":"Jain N","year":"2020","unstructured":"Jain N, Stock W, Zeidan A,  Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood Adv 2020;4:449\u2013457."},{"key":"B23","series-title":"Pediatr Blood Cancer","first-page":"e28112","article-title":"Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia","volume":"67","author":"Shah NN","year":"2020","unstructured":"Shah NN, Bhojwani D, August K,  Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia. Pediatr Blood Cancer 2020;67:e28112."},{"key":"B24","series-title":"N Engl J Med","first-page":"740","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian HM","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M,  Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;375:740\u2013753."},{"key":"B25","series-title":"Leukemia","first-page":"884","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani D","year":"2019","unstructured":"Bhojwani D, Sposto R, Shah NN,  Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia 2019;33:884\u2013892."},{"key":"B26","series-title":"Lancet Oncol","first-page":"240","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian H","year":"2018","unstructured":"Kantarjian H, Ravandi F, Short NJ,  Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2018;19:240\u2013248."},{"key":"B27","series-title":"Lancet Haematol","first-page":"e433","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour E","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J,  Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 2023;10:e433\u2013444."},{"key":"B28","series-title":"J Clin Oncol","first-page":"273","article-title":"Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL","volume":"42","author":"Stelljes M","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N,  Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL. J Clin Oncol 2024;42:273\u2013282."},{"key":"B29","series-title":"J Clin Oncol","first-page":"4327","article-title":"Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22(+) Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Chevallier P","year":"2024","unstructured":"Chevallier P, Leguay T, Delord M,  Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22(+) Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. J Clin Oncol 2024;42:4327\u20134341."},{"key":"B30","series-title":"Blood","first-page":"308","article-title":"Addition of inotuzumab to a pediatric inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the Alliance A041501 phase 3 randomized trial","volume":"144","author":"DeAngelo DJ","year":"2024","unstructured":"DeAngelo DJ, Yin J, Advani AS,  Addition of inotuzumab to a pediatric inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the Alliance A041501 phase 3 randomized trial. Blood 2024;144(Suppl 1):Abstract 308."},{"key":"B31","series-title":"Blood","first-page":"3398","article-title":"A phase 3 randomized trial of inotuzumab ozogamicin for newly diagnosed high-risk B-ALL: safety phase results from Children's Oncology Group protocol AALL1732","volume":"138","author":"McNeer JL","year":"2021","unstructured":"McNeer JL, O\u2019Brien MM, Rheingold SR,  A phase 3 randomized trial of inotuzumab ozogamicin for newly diagnosed high-risk B-ALL: safety phase results from Children's Oncology Group protocol AALL1732. Blood 2021;138(Suppl 1):Abstract 3398."},{"key":"B32","series-title":"Science","first-page":"974","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou R","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G,  Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974\u2013977."},{"key":"B33","series-title":"J Clin Oncol","first-page":"2493","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp MS","year":"2011","unstructured":"Topp MS, Kufer P, Gokbuget N,  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493\u20132498."},{"key":"B34","series-title":"Lancet Oncol","first-page":"57","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp MS","year":"2015","unstructured":"Topp MS, Gokbuget N, Stein AS,  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57\u201366."},{"key":"B35","series-title":"Cancer","first-page":"2178","article-title":"Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies","volume":"122","author":"Kantarjian HM","year":"2016","unstructured":"Kantarjian HM, Stein AS, Bargou RC,  Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer 2016;122:2178\u20132185."},{"key":"B36","series-title":"N Engl J Med","first-page":"836","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian H","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N,  Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017;376:836\u2013847."},{"key":"B37","series-title":"Blood","first-page":"1522","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget N","year":"2018","unstructured":"Gokbuget N, Dombret H, Bonifacio M,  Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018;131:1522\u20131531."},{"key":"B38","series-title":"Leuk Lymphoma","first-page":"2665","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"Gokbuget N","year":"2020","unstructured":"Gokbuget N, Zugmaier G, Dombret H,  Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 2020;61:2665\u20132673."},{"key":"B39","series-title":"N Engl J Med","first-page":"320","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow MR","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ,  Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med 2024;391:320\u2013333."},{"key":"B40","series-title":"J Clin Oncol","first-page":"4381","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg A","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G,  Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol 2016;34:4381\u20134389."},{"key":"B41","series-title":"J Clin Oncol","first-page":"4118","article-title":"Children's Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan LE","year":"2023","unstructured":"Hogan LE, Brown PA, Ji L,  Children's Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse. J Clin Oncol 2023;41:4118\u20134129."},{"key":"B42","series-title":"Blood","first-page":"1","article-title":"Blinatumomab added to chemotherapy inproves disease-free survival in newy diagnosed NCI standard risk pediatric B-acute lymphoblastic leukemia: results from the radomized Children\u2019s Oncology Group study AALL1731","volume":"144","author":"Rau RE","year":"2024","unstructured":"Rau RE, Gupta S, Kairalla JA,  Blinatumomab added to chemotherapy inproves disease-free survival in newy diagnosed NCI standard risk pediatric B-acute lymphoblastic leukemia: results from the radomized Children\u2019s Oncology Group study AALL1731. Blood 2024;144(Suppl 1):Abstract 1."},{"key":"B43","series-title":"N Engl J Med","first-page":"1613","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Foa R","year":"2020","unstructured":"Foa R, Bassan R, Vitale A,  Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med 2020;383:1613\u20131623."},{"key":"B44","series-title":"J Clin Oncol","first-page":"881","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Foa R","year":"2024","unstructured":"Foa R, Bassan R, Elia L,  Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol 2024;42:881\u2013885."},{"key":"B45","series-title":"Lancet Haematol","first-page":"e24","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour E","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N,  Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 2023;10:e24\u201334."},{"key":"B46","series-title":"J Clin Oncol","first-page":"1574","article-title":"SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani AS","year":"2022","unstructured":"Advani AS, Moseley A, O\u2019Dwyer KM,  SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. J Clin Oncol 2022;40:1574\u20131582."},{"key":"B47","series-title":"J Clin Oncol","first-page":"907","article-title":"Blinatumomab for first-line treatment of children and young persons with B-ALL","volume":"42","author":"Hodder A","year":"2024","unstructured":"Hodder A, Mishra AK, Enshaei A,  Blinatumomab for first-line treatment of children and young persons with B-ALL. J Clin Oncol 2024;42:907\u2013914."},{"key":"B48","series-title":"Blood","first-page":"2304","article-title":"Blinatumomab associated seizure risk in patients with Down Syndrome and B-lymphoblastic leukemia: an interim report from Children's Oncology Group (COG) study AALL1731","volume":"138","author":"Li AM","year":"2021","unstructured":"Li AM, Rabin KR, Kairalla J,  Blinatumomab associated seizure risk in patients with Down Syndrome and B-lymphoblastic leukemia: an interim report from Children's Oncology Group (COG) study AALL1731. Blood 2021;138(Suppl 1):Abstract 2304."},{"key":"B49","series-title":"Blood Res","first-page":"135","article-title":"Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk","volume":"57","author":"Wo S","year":"2022","unstructured":"Wo S, Levavi H, Mascarenhas J,  Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk. Blood Res 2022;57:135\u2013143."},{"key":"B50","series-title":"Blood Cancer J","first-page":"e244","article-title":"Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia","volume":"4","author":"Zugmaier G","year":"2014","unstructured":"Zugmaier G, Topp MS, Alekar S,  Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J 2014;4:e244."},{"key":"B51","series-title":"Nat Biotechnol","first-page":"70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher J","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G,  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor. Nat Biotechnol 2002;20:70\u201375."},{"key":"B52","series-title":"Leukemia","first-page":"676","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai C","year":"2004","unstructured":"Imai C, Mihara K, Andreansky M,  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004;18:676\u2013684."},{"key":"B53","series-title":"N Engl J Med","first-page":"64","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June CH","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med 2018;379:64\u201373."},{"key":"B54","series-title":"Blood Rev","first-page":"45","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno JN","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 2019;34:45\u201355."},{"key":"B55","series-title":"N Engl J Med","first-page":"1509","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp SA","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D,  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509\u20131518."},{"key":"B56","series-title":"Blood","first-page":"3322","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner RA","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C,  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 2017;129:3322\u20133331."},{"key":"B57","series-title":"Lancet","first-page":"517","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee DW","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M,  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517\u2013528."},{"key":"B58","series-title":"N Engl J Med","first-page":"449","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park JH","year":"2018","unstructured":"Park JH, Riviere I, Gonen M,  Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018;378:449\u2013459."},{"key":"B59","series-title":"Clin Adv Hematol Oncol","first-page":"664","article-title":"Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia","volume":"16","author":"Maude SL","year":"2018","unstructured":"Maude SL. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2018;16:664\u2013666."},{"key":"B60","series-title":"Lancet","first-page":"491","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah BD","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO,  KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 2021;398:491\u2013502."},{"key":"B61","series-title":"N Engl J Med","first-page":"2219","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie C","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E,  Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med 2024;391:2219\u20132230."},{"key":"B62","series-title":"J Clin Oncol","first-page":"1664","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch TW","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S,  Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol 2023;41:1664\u20131669."},{"key":"B63","series-title":"J Clin Oncol","first-page":"1650","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah NN","year":"2021","unstructured":"Shah NN, Lee DW, Yates B,  Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol 2021;39:1650\u20131659."},{"key":"B64","series-title":"Am J Hematol","first-page":"E162","article-title":"Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed\/refractory pediatric acute lymphoblastic leukemia","volume":"96","author":"Wang S","year":"2021","unstructured":"Wang S, Wang X, Ye C,  Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed\/refractory pediatric acute lymphoblastic leukemia. Am J Hematol 2021;96:E162\u2013165."},{"key":"B65","series-title":"Nat Commun","first-page":"5928","article-title":"Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia","volume":"11","author":"An F","year":"2020","unstructured":"An F, Wang H, Liu Z,  Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia. Nat Commun 2020;11:5928."},{"key":"B66","series-title":"Br J Haematol","first-page":"475","article-title":"Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia","volume":"197","author":"Jacoby E","year":"2022","unstructured":"Jacoby E, Bielorai B, Hutt D,  Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia. Br J Haematol 2022;197:475\u2013481."},{"key":"B67","series-title":"J Clin Oncol","first-page":"945","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz LM","year":"2022","unstructured":"Schultz LM, Baggott C, Prabhu S,  Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol 2022;40:945\u2013955."},{"key":"B68","series-title":"Leuk Lymphoma","first-page":"1098","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi S","year":"2011","unstructured":"Raponi S, De Propris MS, Intoppa S,  Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011;52:1098\u20131107."},{"key":"B69","series-title":"Blood","first-page":"1165","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso W","year":"2013","unstructured":"Haso W, Lee DW, Shah NN,  Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2013;121:1165\u20131174."},{"key":"B70","series-title":"Pediatr Blood Cancer","first-page":"964","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah NN","year":"2015","unstructured":"Shah NN, Stevenson MS, Yuan CM,  Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer 2015;62:964\u2013969."},{"key":"B71","series-title":"Nat Med","first-page":"20","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry TJ","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ,  CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018;24:20\u201328."},{"key":"B72","series-title":"Leukemia","first-page":"963","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results","volume":"38","author":"Schultz LM","year":"2024","unstructured":"Schultz LM, Jeyakumar N, Kramer AM,  CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results. Leukemia 2024;38:963\u2013968."},{"key":"B73","series-title":"Mol Ther Oncolytics","first-page":"127","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting Both CD19 and CD22","volume":"11","author":"Qin H","year":"2018","unstructured":"Qin H, Ramakrishna S, Nguyen S,  Preclinical development of bivalent chimeric antigen receptors targeting Both CD19 and CD22. Mol Ther Oncolytics 2018;11:127\u2013137."},{"key":"B74","series-title":"Nat Med","first-page":"1797","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba S","year":"2021","unstructured":"Cordoba S, Onuoha S, Thomas S,  CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med 2021;27:1797\u20131805."},{"key":"B75","series-title":"Nat Med","first-page":"1419","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel JY","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L,  CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 2021;27:1419\u20131431."},{"key":"B76","series-title":"J Hematol Oncol","first-page":"53","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai H","year":"2020","unstructured":"Dai H, Wu Z, Jia H,  Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol 2020;13:53."},{"key":"B77","series-title":"Blood Cancer J","first-page":"44","article-title":"CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study","volume":"13","author":"Niu J","year":"2023","unstructured":"Niu J, Qiu H, Xiang F,  CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study. Blood Cancer J 2023;13:44."},{"key":"B78","series-title":"Blood","first-page":"451","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi H","year":"2022","unstructured":"Shalabi H, Qin H, Su A,  CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood 2022;140:451\u2013463."},{"key":"B79","series-title":"Blood","first-page":"278","article-title":"Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia","volume":"132","author":"Gardner R","year":"2018","unstructured":"Gardner R, Annesley C, Finney O,  Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia. Blood 2018;132(Suppl 1):Abstract 278."},{"key":"B80","series-title":"Blood","first-page":"470","article-title":"SCRI-CAR19x22v2 T cell product demonstrates bispecific activity in B-ALL","volume":"138","author":"Annesley C","year":"2021","unstructured":"Annesley C, Summers C, Pulsipher MA,  SCRI-CAR19x22v2 T cell product demonstrates bispecific activity in B-ALL. Blood 2021;138(Suppl 1):Abstract 470."},{"key":"B81","series-title":"Blood","first-page":"10352","article-title":"Dual antigen targeting with co-transduced CD19\/22 CAR T cells may prevent antigen-negative relapse after CAR T cell therapy for relapsed\/refractory ALL","volume":"140","author":"Ghorashian S","year":"2022","unstructured":"Ghorashian S, Lucchini G, Richardson R,  Dual antigen targeting with co-transduced CD19\/22 CAR T cells may prevent antigen-negative relapse after CAR T cell therapy for relapsed\/refractory ALL. Blood 2022;140(Suppl 1):Abstract 10352."},{"key":"B82","series-title":"J Clin Oncol","first-page":"1670","article-title":"Coadministration of CD19- and CD22- directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial","volume":"41","author":"Wang T","year":"2023","unstructured":"Wang T, Tang Y, Cai J,  Coadministration of CD19- and CD22- directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial. J Clin Oncol 2023;41:1670\u20131683."},{"key":"B83","series-title":"Blood","first-page":"17","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang N","year":"2020","unstructured":"Wang N, Hu X, Cao W,  Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood 2020;135:17\u201327."},{"key":"B84","series-title":"Lancet Oncol","first-page":"1229","article-title":"Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study","volume":"24","author":"Pan J","year":"2023","unstructured":"Pan J, Tang K, Luo Y,  Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2023;24:1229\u20131241."},{"key":"B85","series-title":"Am J Hematol","first-page":"671","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu S","year":"2021","unstructured":"Liu S, Deng B, Yin Z,  Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol 2021;96:671\u2013679."},{"key":"B86","series-title":"Cancer Discov","first-page":"2032","article-title":"Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A\/MLL1-rearranged B-ALL","volume":"11","author":"Nix MA","year":"2021","unstructured":"Nix MA, Mandal K, Geng H,  Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A\/MLL1-rearranged B-ALL. Cancer Discov 2021;11:2032\u20132049."},{"key":"B87","series-title":"Blood","first-page":"2406","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner R","year":"2016","unstructured":"Gardner R, Wu D, Cherian S,  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 2016;127:2406\u20132410."},{"key":"B88","series-title":"J Immunother Cancer","article-title":"Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies","volume":"11","author":"Temple WC","year":"2023","unstructured":"Temple WC, Nix MA, Naik A,  Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies. J Immunother Cancer 2023;11:e006985."},{"key":"B89","series-title":"Blood","first-page":"629","article-title":"Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein","volume":"126","author":"Qin H","year":"2015","unstructured":"Qin H, Cho M, Haso W,  Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood 2015;126:629\u2013639."},{"key":"B90","series-title":"N Engl J Med","first-page":"1005","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts KG","year":"2014","unstructured":"Roberts KG, Li Y, Payne-Turner D,  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014;371:1005\u20131015."},{"key":"B91","series-title":"Blood","first-page":"1705","article-title":"Precision co-targeting of the thymic stromal lymphopoietin receptor in childhood CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Bagashev A","year":"2021","unstructured":"Bagashev A, Loftus JP, Ross S,  Precision co-targeting of the thymic stromal lymphopoietin receptor in childhood CRLF2-rearranged acute lymphoblastic leukemia. Blood 2021;138(Suppl 1):Abstract 1705."},{"key":"B92","series-title":"Hemasphere","first-page":"e08838b7","article-title":"S117: Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly-diagnosed, Ph-negative, Cd22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703","volume":"7","author":"Wieduwilt M","year":"2023","unstructured":"Wieduwilt M, Yin J, Kour O,  S117: Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly-diagnosed, Ph-negative, Cd22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703. Hemasphere 2023;7:e08838b7."},{"key":"B93","series-title":"Blood","first-page":"1908","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa MR","year":"2022","unstructured":"Gaballa MR, Banerjee P, Milton DR,  Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood 2022;139:1908\u20131919."},{"key":"B1","series-title":"N Engl J Med","first-page":"1541","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger SP","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med 2015;373:1541\u20131552."},{"key":"B2","series-title":"J Clin Oncol","first-page":"2938","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui CH","year":"2015","unstructured":"Pui CH, Yang JJ, Hunger SP,  Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol 2015;33:2938\u20132948."},{"key":"B3","series-title":"Pediatr Blood Cancer","first-page":"e30585","article-title":"Children's Oncology Group blueprint for research: acute lymphoblastic leukemia","volume":"70","author":"Raetz EA","year":"2023","unstructured":"Raetz EA, Bhojwani D, Devidas M,  Children's Oncology Group blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer 2023;70(Suppl 6):e30585."},{"key":"B4","series-title":"N Engl J Med","first-page":"875","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta S","year":"2025","unstructured":"Gupta S, Rau RE, Kairalla JA,  Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N Engl J Med 2025;392:875\u2013891."},{"key":"B5","series-title":"N Engl J Med","first-page":"1572","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis IM","year":"2023","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS,  Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med 2023;388:1572\u20131581."},{"key":"B6","series-title":"JAMA","first-page":"833","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown PA","year":"2021","unstructured":"Brown PA, Ji L, Xu X,  Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA 2021;325:833\u2013842."},{"key":"B7","series-title":"JAMA","first-page":"843","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli F","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C,  Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA 2021;325:843\u2013854."},{"key":"B8","series-title":"J Clin Oncol","first-page":"956","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group protocol AALL1621","volume":"40","author":"O\u2019Brien MM","year":"2022","unstructured":"O\u2019Brien MM, Ji L, Shah NN,  Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group protocol AALL1621. J Clin Oncol 2022;40:956\u2013967."},{"key":"B9","series-title":"N Engl J Med","first-page":"1507","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude SL","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA,  Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507\u20131517."},{"key":"B10","series-title":"N Engl J Med","first-page":"439","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude SL","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J,  Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439\u2013448."},{"key":"B11","series-title":"N Engl J Med","first-page":"1044","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury S","year":"2016","unstructured":"Maury S, Chevret S, Thomas X,  Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med 2016;375:1044\u20131053."},{"key":"B12","series-title":"J Clin Oncol","first-page":"3880","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas DA","year":"2010","unstructured":"Thomas DA, O\u2019Brien S, Faderl S,  Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010;28:3880\u20133889."},{"key":"B13","series-title":"Blood","first-page":"4018","article-title":"A phase II study of pegylated asparaginase, cyclophosphamide, rituximab, and dasatinib added to the UCSF 8707 (Linker 4-drug) regimen with liposomal cytarabine CNS prophylaxis for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401","volume":"132","author":"Wieduwilt MJ","year":"2018","unstructured":"Wieduwilt MJ, Jonas BA, Schiller GJ,  A phase II study of pegylated asparaginase, cyclophosphamide, rituximab, and dasatinib added to the UCSF 8707 (Linker 4-drug) regimen with liposomal cytarabine CNS prophylaxis for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401. Blood 2018;132(Suppl 1):Abstract 4018."},{"key":"B14","series-title":"Blood","first-page":"1493","article-title":"Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL)","volume":"120","author":"Goekbuget N","year":"2012","unstructured":"Goekbuget N, Beck J, Brueggemann M,  Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL). Blood 2012;120(Suppl):Abstract 1493."},{"key":"B15","series-title":"Blood","first-page":"1903","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget N","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S,  Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood 2024;143:1903\u20131930."},{"key":"B16","series-title":"Leukemia","first-page":"1782","article-title":"Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia","volume":"37","author":"Hoshitsuki K","year":"2023","unstructured":"Hoshitsuki K, Zhou Y, Miller AM,  Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia. Leukemia 2023;37:1782\u20131791."},{"key":"B17","series-title":"Cancer","first-page":"3381","article-title":"Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis","volume":"127","author":"Sasaki K","year":"2021","unstructured":"Sasaki K, Kantarjian HM, Morita K,  Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis. Cancer 2021;127:3381\u20133389."},{"key":"B18","series-title":"J Immunol","first-page":"362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling JL","year":"2006","unstructured":"Teeling JL, Mackus WJ, Wiegman LJ,  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362\u2013371."},{"key":"B19","series-title":"Lancet Haematol","first-page":"e523","article-title":"Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial","volume":"7","author":"Jabbour E","year":"2020","unstructured":"Jabbour E, Richard-Carpentier G, Sasaki Y,  Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 2020;7:e523\u2013533."},{"key":"B20","series-title":"Br J Haematol","first-page":"763","article-title":"Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive\/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia","volume":"171","author":"Awasthi A","year":"2015","unstructured":"Awasthi A, Ayello J, Van de Ven C,  Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive\/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia. Br J Haematol 2015;171:763\u2013775."},{"key":"B21","series-title":"Pediatr Blood Cancer","first-page":"1171","article-title":"Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children's Oncology Group (COG) study ADVL04P2","volume":"62","author":"Raetz EA","year":"2015","unstructured":"Raetz EA, Cairo MS, Borowitz MJ,  Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatr Blood Cancer 2015;62:1171\u20131175."},{"key":"B22","series-title":"Blood Adv","first-page":"449","article-title":"Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"4","author":"Jain N","year":"2020","unstructured":"Jain N, Stock W, Zeidan A,  Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood Adv 2020;4:449\u2013457."},{"key":"B23","series-title":"Pediatr Blood Cancer","first-page":"e28112","article-title":"Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia","volume":"67","author":"Shah NN","year":"2020","unstructured":"Shah NN, Bhojwani D, August K,  Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia. Pediatr Blood Cancer 2020;67:e28112."},{"key":"B24","series-title":"N Engl J Med","first-page":"740","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian HM","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M,  Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;375:740\u2013753."},{"key":"B25","series-title":"Leukemia","first-page":"884","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani D","year":"2019","unstructured":"Bhojwani D, Sposto R, Shah NN,  Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia 2019;33:884\u2013892."},{"key":"B26","series-title":"Lancet Oncol","first-page":"240","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian H","year":"2018","unstructured":"Kantarjian H, Ravandi F, Short NJ,  Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2018;19:240\u2013248."},{"key":"B27","series-title":"Lancet Haematol","first-page":"e433","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour E","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J,  Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 2023;10:e433\u2013444."},{"key":"B28","series-title":"J Clin Oncol","first-page":"273","article-title":"Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL","volume":"42","author":"Stelljes M","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N,  Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL. J Clin Oncol 2024;42:273\u2013282."},{"key":"B29","series-title":"J Clin Oncol","first-page":"4327","article-title":"Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22(+) Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Chevallier P","year":"2024","unstructured":"Chevallier P, Leguay T, Delord M,  Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22(+) Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. J Clin Oncol 2024;42:4327\u20134341."},{"key":"B30","series-title":"Blood","first-page":"308","article-title":"Addition of inotuzumab to a pediatric inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the Alliance A041501 phase 3 randomized trial","volume":"144","author":"DeAngelo DJ","year":"2024","unstructured":"DeAngelo DJ, Yin J, Advani AS,  Addition of inotuzumab to a pediatric inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the Alliance A041501 phase 3 randomized trial. Blood 2024;144(Suppl 1):Abstract 308."},{"key":"B31","series-title":"Blood","first-page":"3398","article-title":"A phase 3 randomized trial of inotuzumab ozogamicin for newly diagnosed high-risk B-ALL: safety phase results from Children's Oncology Group protocol AALL1732","volume":"138","author":"McNeer JL","year":"2021","unstructured":"McNeer JL, O\u2019Brien MM, Rheingold SR,  A phase 3 randomized trial of inotuzumab ozogamicin for newly diagnosed high-risk B-ALL: safety phase results from Children's Oncology Group protocol AALL1732. Blood 2021;138(Suppl 1):Abstract 3398."},{"key":"B32","series-title":"Science","first-page":"974","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou R","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G,  Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974\u2013977."},{"key":"B33","series-title":"J Clin Oncol","first-page":"2493","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp MS","year":"2011","unstructured":"Topp MS, Kufer P, Gokbuget N,  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493\u20132498."},{"key":"B34","series-title":"Lancet Oncol","first-page":"57","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp MS","year":"2015","unstructured":"Topp MS, Gokbuget N, Stein AS,  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57\u201366."},{"key":"B35","series-title":"Cancer","first-page":"2178","article-title":"Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies","volume":"122","author":"Kantarjian HM","year":"2016","unstructured":"Kantarjian HM, Stein AS, Bargou RC,  Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer 2016;122:2178\u20132185."},{"key":"B36","series-title":"N Engl J Med","first-page":"836","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian H","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N,  Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017;376:836\u2013847."},{"key":"B37","series-title":"Blood","first-page":"1522","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget N","year":"2018","unstructured":"Gokbuget N, Dombret H, Bonifacio M,  Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018;131:1522\u20131531."},{"key":"B38","series-title":"Leuk Lymphoma","first-page":"2665","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"Gokbuget N","year":"2020","unstructured":"Gokbuget N, Zugmaier G, Dombret H,  Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 2020;61:2665\u20132673."},{"key":"B39","series-title":"N Engl J Med","first-page":"320","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow MR","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ,  Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med 2024;391:320\u2013333."},{"key":"B40","series-title":"J Clin Oncol","first-page":"4381","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg A","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G,  Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol 2016;34:4381\u20134389."},{"key":"B41","series-title":"J Clin Oncol","first-page":"4118","article-title":"Children's Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan LE","year":"2023","unstructured":"Hogan LE, Brown PA, Ji L,  Children's Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse. J Clin Oncol 2023;41:4118\u20134129."},{"key":"B42","series-title":"Blood","first-page":"1","article-title":"Blinatumomab added to chemotherapy inproves disease-free survival in newy diagnosed NCI standard risk pediatric B-acute lymphoblastic leukemia: results from the radomized Children\u2019s Oncology Group study AALL1731","volume":"144","author":"Rau RE","year":"2024","unstructured":"Rau RE, Gupta S, Kairalla JA,  Blinatumomab added to chemotherapy inproves disease-free survival in newy diagnosed NCI standard risk pediatric B-acute lymphoblastic leukemia: results from the radomized Children\u2019s Oncology Group study AALL1731. Blood 2024;144(Suppl 1):Abstract 1."},{"key":"B43","series-title":"N Engl J Med","first-page":"1613","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Foa R","year":"2020","unstructured":"Foa R, Bassan R, Vitale A,  Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med 2020;383:1613\u20131623."},{"key":"B44","series-title":"J Clin Oncol","first-page":"881","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Foa R","year":"2024","unstructured":"Foa R, Bassan R, Elia L,  Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol 2024;42:881\u2013885."},{"key":"B45","series-title":"Lancet Haematol","first-page":"e24","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour E","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N,  Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 2023;10:e24\u201334."},{"key":"B46","series-title":"J Clin Oncol","first-page":"1574","article-title":"SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani AS","year":"2022","unstructured":"Advani AS, Moseley A, O\u2019Dwyer KM,  SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. J Clin Oncol 2022;40:1574\u20131582."},{"key":"B47","series-title":"J Clin Oncol","first-page":"907","article-title":"Blinatumomab for first-line treatment of children and young persons with B-ALL","volume":"42","author":"Hodder A","year":"2024","unstructured":"Hodder A, Mishra AK, Enshaei A,  Blinatumomab for first-line treatment of children and young persons with B-ALL. J Clin Oncol 2024;42:907\u2013914."},{"key":"B48","series-title":"Blood","first-page":"2304","article-title":"Blinatumomab associated seizure risk in patients with Down Syndrome and B-lymphoblastic leukemia: an interim report from Children's Oncology Group (COG) study AALL1731","volume":"138","author":"Li AM","year":"2021","unstructured":"Li AM, Rabin KR, Kairalla J,  Blinatumomab associated seizure risk in patients with Down Syndrome and B-lymphoblastic leukemia: an interim report from Children's Oncology Group (COG) study AALL1731. Blood 2021;138(Suppl 1):Abstract 2304."},{"key":"B49","series-title":"Blood Res","first-page":"135","article-title":"Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk","volume":"57","author":"Wo S","year":"2022","unstructured":"Wo S, Levavi H, Mascarenhas J,  Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk. Blood Res 2022;57:135\u2013143."},{"key":"B50","series-title":"Blood Cancer J","first-page":"e244","article-title":"Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia","volume":"4","author":"Zugmaier G","year":"2014","unstructured":"Zugmaier G, Topp MS, Alekar S,  Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J 2014;4:e244."},{"key":"B51","series-title":"Nat Biotechnol","first-page":"70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher J","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G,  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor. Nat Biotechnol 2002;20:70\u201375."},{"key":"B52","series-title":"Leukemia","first-page":"676","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai C","year":"2004","unstructured":"Imai C, Mihara K, Andreansky M,  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004;18:676\u2013684."},{"key":"B53","series-title":"N Engl J Med","first-page":"64","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June CH","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med 2018;379:64\u201373."},{"key":"B54","series-title":"Blood Rev","first-page":"45","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno JN","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 2019;34:45\u201355."},{"key":"B55","series-title":"N Engl J Med","first-page":"1509","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp SA","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D,  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509\u20131518."},{"key":"B56","series-title":"Blood","first-page":"3322","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner RA","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C,  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 2017;129:3322\u20133331."},{"key":"B57","series-title":"Lancet","first-page":"517","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee DW","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M,  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517\u2013528."},{"key":"B58","series-title":"N Engl J Med","first-page":"449","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park JH","year":"2018","unstructured":"Park JH, Riviere I, Gonen M,  Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018;378:449\u2013459."},{"key":"B59","series-title":"Clin Adv Hematol Oncol","first-page":"664","article-title":"Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia","volume":"16","author":"Maude SL","year":"2018","unstructured":"Maude SL. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2018;16:664\u2013666."},{"key":"B60","series-title":"Lancet","first-page":"491","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah BD","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO,  KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 2021;398:491\u2013502."},{"key":"B61","series-title":"N Engl J Med","first-page":"2219","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie C","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E,  Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med 2024;391:2219\u20132230."},{"key":"B62","series-title":"J Clin Oncol","first-page":"1664","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch TW","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S,  Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol 2023;41:1664\u20131669."},{"key":"B63","series-title":"J Clin Oncol","first-page":"1650","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah NN","year":"2021","unstructured":"Shah NN, Lee DW, Yates B,  Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol 2021;39:1650\u20131659."},{"key":"B64","series-title":"Am J Hematol","first-page":"E162","article-title":"Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed\/refractory pediatric acute lymphoblastic leukemia","volume":"96","author":"Wang S","year":"2021","unstructured":"Wang S, Wang X, Ye C,  Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed\/refractory pediatric acute lymphoblastic leukemia. Am J Hematol 2021;96:E162\u2013165."},{"key":"B65","series-title":"Nat Commun","first-page":"5928","article-title":"Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia","volume":"11","author":"An F","year":"2020","unstructured":"An F, Wang H, Liu Z,  Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia. Nat Commun 2020;11:5928."},{"key":"B66","series-title":"Br J Haematol","first-page":"475","article-title":"Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia","volume":"197","author":"Jacoby E","year":"2022","unstructured":"Jacoby E, Bielorai B, Hutt D,  Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia. Br J Haematol 2022;197:475\u2013481."},{"key":"B67","series-title":"J Clin Oncol","first-page":"945","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz LM","year":"2022","unstructured":"Schultz LM, Baggott C, Prabhu S,  Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol 2022;40:945\u2013955."},{"key":"B68","series-title":"Leuk Lymphoma","first-page":"1098","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi S","year":"2011","unstructured":"Raponi S, De Propris MS, Intoppa S,  Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011;52:1098\u20131107."},{"key":"B69","series-title":"Blood","first-page":"1165","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso W","year":"2013","unstructured":"Haso W, Lee DW, Shah NN,  Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2013;121:1165\u20131174."},{"key":"B70","series-title":"Pediatr Blood Cancer","first-page":"964","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah NN","year":"2015","unstructured":"Shah NN, Stevenson MS, Yuan CM,  Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer 2015;62:964\u2013969."},{"key":"B71","series-title":"Nat Med","first-page":"20","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry TJ","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ,  CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018;24:20\u201328."},{"key":"B72","series-title":"Leukemia","first-page":"963","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results","volume":"38","author":"Schultz LM","year":"2024","unstructured":"Schultz LM, Jeyakumar N, Kramer AM,  CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results. Leukemia 2024;38:963\u2013968."},{"key":"B73","series-title":"Mol Ther Oncolytics","first-page":"127","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting Both CD19 and CD22","volume":"11","author":"Qin H","year":"2018","unstructured":"Qin H, Ramakrishna S, Nguyen S,  Preclinical development of bivalent chimeric antigen receptors targeting Both CD19 and CD22. Mol Ther Oncolytics 2018;11:127\u2013137."},{"key":"B74","series-title":"Nat Med","first-page":"1797","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba S","year":"2021","unstructured":"Cordoba S, Onuoha S, Thomas S,  CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med 2021;27:1797\u20131805."},{"key":"B75","series-title":"Nat Med","first-page":"1419","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel JY","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L,  CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 2021;27:1419\u20131431."},{"key":"B76","series-title":"J Hematol Oncol","first-page":"53","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai H","year":"2020","unstructured":"Dai H, Wu Z, Jia H,  Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol 2020;13:53."},{"key":"B77","series-title":"Blood Cancer J","first-page":"44","article-title":"CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study","volume":"13","author":"Niu J","year":"2023","unstructured":"Niu J, Qiu H, Xiang F,  CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study. Blood Cancer J 2023;13:44."},{"key":"B78","series-title":"Blood","first-page":"451","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi H","year":"2022","unstructured":"Shalabi H, Qin H, Su A,  CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood 2022;140:451\u2013463."},{"key":"B79","series-title":"Blood","first-page":"278","article-title":"Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia","volume":"132","author":"Gardner R","year":"2018","unstructured":"Gardner R, Annesley C, Finney O,  Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia. Blood 2018;132(Suppl 1):Abstract 278."},{"key":"B80","series-title":"Blood","first-page":"470","article-title":"SCRI-CAR19x22v2 T cell product demonstrates bispecific activity in B-ALL","volume":"138","author":"Annesley C","year":"2021","unstructured":"Annesley C, Summers C, Pulsipher MA,  SCRI-CAR19x22v2 T cell product demonstrates bispecific activity in B-ALL. Blood 2021;138(Suppl 1):Abstract 470."},{"key":"B81","series-title":"Blood","first-page":"10352","article-title":"Dual antigen targeting with co-transduced CD19\/22 CAR T cells may prevent antigen-negative relapse after CAR T cell therapy for relapsed\/refractory ALL","volume":"140","author":"Ghorashian S","year":"2022","unstructured":"Ghorashian S, Lucchini G, Richardson R,  Dual antigen targeting with co-transduced CD19\/22 CAR T cells may prevent antigen-negative relapse after CAR T cell therapy for relapsed\/refractory ALL. Blood 2022;140(Suppl 1):Abstract 10352."},{"key":"B82","series-title":"J Clin Oncol","first-page":"1670","article-title":"Coadministration of CD19- and CD22- directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial","volume":"41","author":"Wang T","year":"2023","unstructured":"Wang T, Tang Y, Cai J,  Coadministration of CD19- and CD22- directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial. J Clin Oncol 2023;41:1670\u20131683."},{"key":"B83","series-title":"Blood","first-page":"17","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang N","year":"2020","unstructured":"Wang N, Hu X, Cao W,  Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood 2020;135:17\u201327."},{"key":"B84","series-title":"Lancet Oncol","first-page":"1229","article-title":"Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study","volume":"24","author":"Pan J","year":"2023","unstructured":"Pan J, Tang K, Luo Y,  Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2023;24:1229\u20131241."},{"key":"B85","series-title":"Am J Hematol","first-page":"671","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu S","year":"2021","unstructured":"Liu S, Deng B, Yin Z,  Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol 2021;96:671\u2013679."},{"key":"B86","series-title":"Cancer Discov","first-page":"2032","article-title":"Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A\/MLL1-rearranged B-ALL","volume":"11","author":"Nix MA","year":"2021","unstructured":"Nix MA, Mandal K, Geng H,  Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A\/MLL1-rearranged B-ALL. Cancer Discov 2021;11:2032\u20132049."},{"key":"B87","series-title":"Blood","first-page":"2406","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner R","year":"2016","unstructured":"Gardner R, Wu D, Cherian S,  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 2016;127:2406\u20132410."},{"key":"B88","series-title":"J Immunother Cancer","article-title":"Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies","volume":"11","author":"Temple WC","year":"2023","unstructured":"Temple WC, Nix MA, Naik A,  Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies. J Immunother Cancer 2023;11:e006985."},{"key":"B89","series-title":"Blood","first-page":"629","article-title":"Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein","volume":"126","author":"Qin H","year":"2015","unstructured":"Qin H, Cho M, Haso W,  Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood 2015;126:629\u2013639."},{"key":"B90","series-title":"N Engl J Med","first-page":"1005","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts KG","year":"2014","unstructured":"Roberts KG, Li Y, Payne-Turner D,  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014;371:1005\u20131015."},{"key":"B91","series-title":"Blood","first-page":"1705","article-title":"Precision co-targeting of the thymic stromal lymphopoietin receptor in childhood CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Bagashev A","year":"2021","unstructured":"Bagashev A, Loftus JP, Ross S,  Precision co-targeting of the thymic stromal lymphopoietin receptor in childhood CRLF2-rearranged acute lymphoblastic leukemia. Blood 2021;138(Suppl 1):Abstract 1705."},{"key":"B92","series-title":"Hemasphere","first-page":"e08838b7","article-title":"S117: Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly-diagnosed, Ph-negative, Cd22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703","volume":"7","author":"Wieduwilt M","year":"2023","unstructured":"Wieduwilt M, Yin J, Kour O,  S117: Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly-diagnosed, Ph-negative, Cd22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703. Hemasphere 2023;7:e08838b7."},{"key":"B93","series-title":"Blood","first-page":"1908","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa MR","year":"2022","unstructured":"Gaballa MR, Banerjee P, Milton DR,  Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood 2022;139:1908\u20131919."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/12\/article-e257067.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/12\/article-e257067.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/12\/article-e257067.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:56:19Z","timestamp":1765979779000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/12\/article-e257067.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":186,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7067","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}